EFEvgenij G. Furman

Evgenij G. Furman

*This is an algorithmically generated author record based on publicly available information.

Evgenij G. Furman has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transformer Architectures for Respiratory Sound Analysis and Multimodal Diagnosis

    by Theodore Aptekarev, Vladimir Sokolovsky, Gregory Furman, Evgeny Furman

    Breath sound analysis is one of the diagnostic approaches for various lung diseases. However, traditional auscultation is subjective and dependent on the physician’s experience. Recent studies have demonstrated that computer-assisted methods analyzing these sounds can significantly improve the accuracy of diagnosis of the patient’s condition. However, the absence of a common basis for fair comparison, limited use of patient metadata, and lack of interpretability make these approaches difficult to adopt in clinical practice. In the paper, we propose to utilize the benefits of the recent state-of-the-art sound classification models and a multimodal approach for respiratory disease screening and diagnostics. To achieve this goal, we use the Audio Spectrogram Transformer (AST) model and a vision-language model (VLM) Moondream2. We compare them with our previous work on the DenseNet201 Convolutional Neural Network (CNN). The proposed methodology allows a fair comparison of different computer-assisted methods for respiratory disease screening and diagnostics. The training and evaluation of the models have been conducted using the same dataset containing respiratory sound recordings and patient information. The obtained results demonstrate that these transformer-based models can serve as a basis for the development of computer-assisted methods for asthma diagnosis, as well as for continuous and remote monitoring of patient condition. In addition, our approach enables interpretability of the model performance. The achieved performance is much better than the best results of the physician’s auscultation.

  • Пневмонии на фоне фармакологической иммуносупрессии: особенности этиологической диагностики

    by Екатерина Александровна Хузина, Евгений Григорьевич Фурман, Анастасия Алексеевна Кильдибекова

    До настоящего времени в отношении пациентов с иммунодефицитными состояниями, индуцированными иммунобиологическими препаратами, нет определенного понимания, что именно приводит к иммуносупрессии у этих больных: первичное нарушение координации иммунных клеток или следствие фармакотерапии. Вместе с тем на сегодняшний день в связи со значительным прогрессом в терапии иммунопатологических заболеваний растет число изначально иммунокомпетентных пациентов, получающих различные биологические агенты: ингибиторы интерлейкина (ИЛ) -1, ИЛ-6, ИЛ-12/ИЛ-23, ингибиторы тирозинкиназы, В-лимфоцитарного фактора роста, костимулирующих молекул. Биологические препараты, вмешиваясь в процессы провоспалительных реакций, миграцию и активацию иммунных клеток, нарушают сигнальные пути, тем самым препятствуют иммунному ответу и увеличивают риск инфекции. Особенности течения инфекций нижних дыхательных путей у детей, получающих различные виды биологической иммуносупрессивной терапии, в настоящее время изучены недостаточно. В статье систематизированы литературные данные, позволяющие определить факторы риска и тактику этиологической диагностики у этой категории пациентов. To date, there is no clear understanding regarding patients with immunodeficiency states induced by immunobiological drugs as to what exactly leads to immunosuppression: a primary disruption of immune cell coordination or the consequence of pharmacotherapy. At the same time, due to significant progress in the treatment of immunopathological diseases, the number of initially immunocompetent patients receiving various biological agents is increasing, including inhibitors of interleukin (IL) -1, IL-6, IL-12/IL-23, tyrosine kinase inhibitors, B-cell growth factor inhibitors, and co-stimulatory molecule inhibitors. By interfering with pro-inflammatory responses, migration and activation of immune cells, biological agents disrupt signaling pathways, thereby impairing the immune response and increasing the risk of infection. The characteristics of lower respiratory tract infections in children receiving different types of biological immunosuppressive therapy remain insufficiently studied. This article systematizes literature data that allow identification of risk factors and the development of approaches to etiological diagnosis in this category of patients.

  • Open Access

    Diagnostic capabilities of a portable ultrasound system for lung pathologies, including pneumonia, in children

    by O. S. Baksanova, E. G. Furman

    Objective. Тo evaluate the feasibility, convenience, and effectiveness of diagnosing lung pathologies, including pneumonia, in children using a portable ultrasound system. The use of ultrasound in medical practice has become a landmark breakthrough, significantly improving the quality of care and increasing diagnostic accuracy. In terms of versatility and mobility, portable ultrasound systems with a set of transducers are particularly valuable, enabling high-quality imaging regardless of the patient’s location, while being substantially smaller and lighter. Materials and methods. A comparative study was conducted at the Perm Regional Children's Clinical Hospital. We diagnosed lung diseases, including pneumonia, in children using the Mindray DC 6 and Logic S 8 ultrasound systems, as well as the ELS-MEDТМ ultrasound diagnostic system with a portable transducer (using linear and convex transducers). We compared their diagnostic capabilities, operational features, and the results obtained during the study. Results. The studies showed that 8 children (53.3 %) had interstitial lung changes, 3 children (20 %) had pneumonia, 1 child (6.7 %) had chest masses, and 3 children (20 %) had no pathology. In all 3 children (20 %), lung tissue consolidation was detected in 2 segments, with bilateral lung involvement. Bilateral interstitial changes were found in 8 patients (53.3 %). In one patient with lung consolidation, pneumonia was combined with interstitial changes. Fragment-type lung consolidation was found in 2 children, and consolidation with air bronchogram elements was found in 1 person. No differences were observed in the visualization of lung consolidation areas or interstitial changes between the stationary and portable transducers. The sizes of the lung consolidation areas were practically the same when measured. Interstitial changes were clearly visible on both devices. In the study group, one child had chest masses. The portable device also allows clear visualization of the masses, assessment of blood flow, and visualization of the soft-tissue component in the muscle and connective tissue layers, similar to a stationary ultrasound machine. Conclusions. Portable ultrasound devices can be used to diagnose pneumonia, interstitial lung changes, and even tumours in children. We observed no significant differences between the use of stationary and portable ultrasound devices.

  • A clinical case of a neoplasm of the heart in a fourteen years old adolescent

    by E. G. Furman, M. A. Loskutova, A. N. Biyanov, I. V. Botalova, O. E. Nikonova, M. V. Mushinskaya

    Primary cardiac tumors are rare neoplasms affecting the tissues and membranes of the heart. The incidence is 0.002–0.03% in the general population, 0.027–0.08% in children, and 0.02% in adults. Classification of the World Health Organization (2021) distinguish benign and malignant tumors of the heart. In childhood, about 90% of cases are benign cardiac tumors, among them rhabdomyomas are frequent (60–70%). Most malignant neoplasms are represented by sarcomas. In 2% of malignant lesions, an extranodal lesion is diagnosed in non- Hodgkin’s B-cell lymphoma. The clinical picture depends on the size, consistency, localization, nature and growth rate of the tumor, and is represented by symptoms of heart failure, heart defects, rhythm and conduction disorders. There may be manifestations of systemic diseases: fever, weakness, malaise, decreased body weight. Diagnosis of cardiac neoplasms has certain difficulties. As a diagnostic standard, echocardiography and magnetic resonance imaging are used. Invasive diagnostic methods such as angiocardiography and endomyocardial biopsy are of great importance. We present a rare clinical case of cardiac neoplasm in a fourteen-year-old adolescent who was admitted to the oncology department of the Regional Children’s Clinical Hospital of Perm with complaints of chest pain. It is necessary to differentiate benign and malignant tumor with a significant degree of certainty and choose the optimal treatment tactics. In this situation, as salvage therapy, antitumor therapy may be attempted to reduce the tumor mass. A radical method of treatment is heart transplantation.

  • Open Access

    Body plethysmography: national guidelines. Russian Respiratory Society. Russian Association of Specialists in Functional Diagnostics

    by A. V. Cherniak, M. I. Chushkin, Z. R. Aisanov, S. N. Avdeev, Н. Ф. Берестень, A. V. Vorobiev, A. V. Dubakov, E. N. Kalmanova, M. Yu. Kameneva, L. D. Kiryukhina, et al.

    Body plethysmography (synonyms: plethysmography, whole body plethysmography) is an important method for evaluation of the ventilation function of the respiratory system. This method can be used to measure static lung volumes and airway resistance. Methods. This document on body plethysmography was developed by a group of experts from the Russian Respiratory Society and the Russian Association of Specialists in Functional Diagnostics. All experts have experience in conducting research in accordance with quality criteria, analyzing the test results, and developing national standards. Results. Technical standards for body plethysmography were recommended, including criteria for the measurement quality and assessment of the test quality. The experience and knowledge of the expert group members were used in developing these recommendations. Conclusion. The article presents standards for measuring static lung volumes and airway resistance together with an algorithm for interpreting the results. This should contribute to improving the quality of measurements and uniformity in data interpretation.


  • Open Access

    A family case of Shwachman-Diamond syndrome in children with a rare genetic variant of the SBDS gene с.653G>A (p.Arg218Gln)

    by N. N. Grymova, V. V. Shadrina, E. G. Furman

    Shwachman – Diamond syndrome is a hereditary ribosomopathy which is manifested by exocrine pancreatic insufficiency, hematological disorders, stunted growth and bone deformities. The pathology is caused by mutations in the SBDS gene. Early detection of the disease and timely treatment, including the use of enzyme preparations, specialized nutrition and granulocytic colony-stimulating factors, contribute to improving the patients' quality of life and prognosis. A clinical case of a family manifestation of this syndrome is presented in the article. The diagnosis was made and confirmed by a genetic study only at the age of 1. From birth, the girl had clinical manifestations of atopic dermatitis, with a torpid course to therapy, characteristic stools, changes in the general blood test (GBT) in the form of leukopenia and neutropenia of varying severity, changes in the biochemical blood test (BCBT) in the form of increased liver enzymes. Also, the patient has an 8-year-old elder sister with similar changes in the GBT. To exclude the presence of pathogenic genetic variants of the SBDS gene in the cis-position, the girl's parents were examined. A pathogenic variant of the SBDS gene C.258+2TC in a heterozygous state was revealed in the girl's mother, while the father had the variant C.653GA (p.Arg218Gln) in a heterozygous state. Taking into account the hereditary nature of the disease, the girl's elder sister underwent a genetic examination as well at the age of seven. The study also revealed two pathogenic variants of the SBDS gene C.653GA (p.Arg218Gln) and C.258+2TC in a compound heterozygous state. Thus, SDS in the child was confirmed by genetic methods of examination. The case described in the article is aimed at attraction the pediatricians' attention to the correct assessment of GBT indicators (knowledge of age-related norms of the blood cells count and age-specific features of the leukoformula), the ability to count the absolute number of granulocytes. To clarify the nature of neutropenia (congenital, acquired), it is necessary to evaluate the GBT results in dynamics.

  • Current knowledge of bronchial asthma with low T2-inflammation in school-aged children (review)

    by Evgeny G. Furman, Yulia S. Alieva, Ekaterina A. Khuzina

    Bronchial asthma in children is a heterogeneous disease; therefore, determination of the disease endotype is important for personalized therapy, overcoming refractoriness to bronchial asthma treatment, and selecting a targeted biologic drug. The endotype of the disease, which is not associated with eosinophilia and, therefore, characterized by an insufficient response to inhaled corticosteroids, may begin at school age. The prevalence of low T2-inflammatory bronchial asthma in school-aged children is poorly understood, but the evidence presented in this article supports the presence of this endotype. This endotype of bronchial asthma in children is characterized by clinical and pathogenetic features, including low degree of allergic sensitization, reduced level of total IgE, limited number of positive allergy tests, decreased concentration of nitric oxide in exhaled air and eosinophil content in blood. The role of neutrophils in the development and prognosis of bronchial asthma in children is currently insufficiently studied and defined, nevertheless, it is known that the neutrophilic type of inflammation is associated with a more severe course of the disease and inadequate control. It is important to emphasize the need for further research into the endotypes of bronchial asthma in children with the identification of novel biomarkers and molecular mechanisms underlying asthma with low T2-inflammation. This may further enable the achievement of control of bronchial asthma with different inflammatory endotypes.


  • Open Access

    Tolerability of the first inhaled mannitol dose in children with cystic fibrosis

    by V. V. Shadrina, E. K. Zhekaite, A. Yu. Voronkova, V. D. Sherman, Yu. A. Kondakova, Yu. S. Pinegina, A. A. Poloyko, E. G. Furman, E. I. Kondratyeva

    Mannitol for inhalation is recommended for the treatment of cystic fibrosis in children over 6 years of age and adults. Because of the risk of bronchospasm, a challenge test to assess the drug tolerability should be performed prior to prescribing inhalation mannitol. Aim. Tо evaluate the tolerability of the first dose of inhaled mannitol in children with cystic fibrosis. Methods. The mannitol challenge test (according to the instructions for use of the Bronchitol (inhaled mannitol), Pharmaxis Ltd, Australia) was assessed in 81 children aged 6 to 18 years (11.6 ± 3.2 years). The patients were observed in the centers of the Novosibirsk region, the Moscow region, and the Perm region. The patient’s general state, forced expiratory volume in the first second (FEV1), and SpO2 were monitored. Results. Baseline FEV1 data in patients ranged from 30 % to 146 % (87.8 ± 25.7%), and SpO2 was 94 – 99% (97.7 ± 1.3%). 73 (90.1%) patients passed the test. In 8 (9.9%) patients, the following symptoms were observed: bronchospasm (6), laryngospasm (1), and vomiting (1). Bronchial obstruction was treated by inhalation of a bronchodilator, and the children were under observation until the restoration of FEV1. In patients who passed the test, FEV1 ranged from 33 to 149 % (85.4 ± 24.5%), and SpO2 spanned from 95 to 99% (96.7 ± 1.7%). The children who did not pass the test were monitored. One patient passed the test later when targeted therapy was added. Two children did not tolerate other mucolytic drugs (one child – NaCl solution in various dilutions, and the second patient suffering from asthma – dornase alfa). During follow-up, one patient was diagnosed with allergic bronchopulmonary aspergillosis at 12 years of age and with asthma at 13 years of age, which may have influenced the decrease in mannitol tolerability through formation of bronchial hyperreactivity. Thus, true adverse drug reaction in the form of bronchospasm occurred in three children out of 81 (3.7%). Conclusion. 90.1% of patients passed the inhalation mannitol challenge test, and 9.9% of patients did not pass the test. Analysis of adverse drug reactions revealed that only 3.7% of patients experienced true adverse reactions in the form of bronchospasm. During the test, patients were taught the correct technique for inhaling the drug. All the supplies to relieve bronchospasm should be readily available during the test.


  • Open Access

    Age-related features of the choice of inhalers in chilren and adolescents with bronchial asthma and other respiratory diseases

    by E. G. Furman, E. A. Khuzina

    The inhalation way of drug delivery seems to be the most logical for respiratory diseases. However, the most important condition for the effectiveness of inhalation therapy in children and adolescents along with the correct choice of the active substance is the selection of the optimal device and adequate execution of the inspiratory maneuver. When prescribing therapy attention should be paid to the inhalation technique of a particular patient and also take into account the likelihood of side effects when using certain devices. The article provides data on factors affecting the pulmonary deposit of the drug, the internal resistance of various inhalers which have the greatest informativeness for choosing a device along with the assessment of the inspiratory flow rate developed by the patient. The most problematic aspects of drug delivery to the respiratory tract in children under 5 years of age and in patients with inadequate inhalation rate are analyzed. The principles of correct inhalation are discussed which are necessary to obtain an optimal respiratory fraction. It is known that the problem of synchronizing inhalation with the moment of receipt of the drug is the most important when using metered – dose aerosol inhalers. In children this problem can be solved by using a spacer or using nebulizers that convert the liquid form of the drug into an aerosol using compressor air. Individual selection of an inhaler depending on the abilities and preferences of the patient in some groups of patients can significantly increase the effectiveness of therapy without increasing the dose of medications. The article presents up-to-date data on digital inhaler systems and the possibilities of using electronic devices for monitoring and using the inhaler.


  • Association of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of bronchial asthma in children

    by Yu. S. Alieva, E. G. Furman, E. I. Kondratyeva, E. V. Loshkova, V. S. Sokolovsky, M. S. Ponomareva, E. A. Khuzina, R. R. Aishauova

    Objective. To study the association of polymorphic variants HHIP, ADRB2 and IL-33 genes with phenotypes of clinical course of bronchial asthma in children and effective treatment. Materials and methods. 90 patients aged from 5 to 17 with the diagnosis of bronchial asthma were included in the investigation. Diagnostic procedures were carried out in all the patients. They included the study of genetic polymorphism of HHIP, ADRB2 and IL-33 genes to establish the association with the clinical phenotypes, findings of laboratory and instrumental study determining the course of bronchial asthma and the degree of its control. Results. The study of polymorphism of HHIP, ADRB2 and IL-33 genes in children with bronchial asthma with different phenotypes of the disease revealed the association of genetic polymorphism with the severity of course of the disease as well as concomitant diseases. It was determined that allele T of genetic variant rs12504628 (TC) of HHIP gene reduces the risk of a severe course of BA. Its protective role in the development of drug allergy was also proved. Genotype AA of ADRB2 gene is associated with reduced risks of the development of congenital defects of the tracheobronchial tree in BA. Polymorphic variants in the 4th and 6th exon of IL-33 gene are more frequently associated with moderate and severe course of asthma and base substitution in the 4th and 6th exon are associated with the severe course. Conclusions. Associations of polymorphic variants of HHIP, ADRB2 and IL-33 genes with clinical manifestations of BA in children are determined in this study. They can be considered in a personalized monitoring of the patients and can help to control the disease totally.